Related Experiment Video
Updated: Mar 8, 2026
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis
Vanessa Pérez1,2, Dolores López3, Ester Boixadera4
1Laboratory of Experimental Nephrology, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. vperez.igtp@gmail.es.
Background:
Minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS) are glomerular diseases characterized by nephrotic syndrome. Their diagnosis requires a renal biopsy, but it is an invasive procedure with potential complications. In a small biopsy sample, where only normal glomeruli are observed, FSGS cannot be differentiated from MCD. The correct diagnosis is crucial to an effective treatment, as MCD is normally responsive to steroid therapy, whereas FSGS is usually resistant. The purpose of our study was to discover and validate novel early urinary biomarkers capable to differentiate between MCD and FSGS.
Methods:
Forty-nine patients biopsy-diagnosed of MCD and primary FSGS were randomly subdivided into a training set (10 MCD, 11 FSGS) and a validation set (14 MCD, 14 FSGS). The urinary proteome of the training set was analyzed by two-dimensional differential gel electrophoresis coupled with mass spectrometry. The proteins identified were quantified by enzyme-linked immunosorbent assay in urine samples from the validation set.
Results:
Urinary concentration of alpha-1 antitrypsin, transferrin, histatin-3 and 39S ribosomal protein L17 was decreased and calretinin was increased in FSGS compared to MCD. These proteins were used to build a decision tree capable to predict patient's pathology.
Conclusions:
This preliminary study suggests a group of urinary proteins as possible non-invasive biomarkers with potential value in the differential diagnosis of MCD and FSGS. These biomarkers would reduce the number of misdiagnoses, avoiding unnecessary or inadequate treatments.
Insights
Researchers identified novel urinary biomarkers to differentiate Minimal Change Disease (MCD) and primary Focal Segmental Glomerulosclerosis (FSGS). This discovery could lead to non-invasive diagnosis, improving patient treatment by distinguishing steroid-responsive MCD from resistant FSGS.
Area of Science:
- Nephrology
- Proteomics
- Biomarker Discovery
Background:
- Minimal Change Disease (MCD) and primary Focal Segmental Glomerulosclerosis (FSGS) are glomerular diseases causing nephrotic syndrome.
- Renal biopsy is invasive and may not differentiate MCD from FSGS if glomeruli appear normal.
- Accurate diagnosis is vital as MCD responds to steroids, while FSGS is typically resistant.
Purpose of the Study:
- To discover and validate novel early urinary biomarkers.
- To differentiate between MCD and FSGS non-invasively.
Main Methods:
- Analyzed urinary proteome of 49 patients (MCD and FSGS) using 2D differential gel electrophoresis and mass spectrometry.
- Quantified identified proteins via ELISA in a validation set.
- Developed a decision tree model for pathology prediction.
Main Results:
- Decreased urinary concentrations of alpha-1 antitrypsin, transferrin, histatin-3, and 39S ribosomal protein L17 in FSGS compared to MCD.
- Increased urinary concentration of calretinin in FSGS compared to MCD.
- These proteins formed a predictive decision tree.
Conclusions:
- Suggests a panel of urinary proteins as potential non-invasive biomarkers for differentiating MCD and FSGS.
- Potential to reduce misdiagnoses and guide appropriate treatment strategies.
- Highlights the value of urinary proteomic analysis in kidney disease diagnostics.
